Multicenter automatic defibrillator implantation trial–subcutaneous implantable cardioverter defibrillator (madit s-icd): Design and clinical protocol
Recommended Citation
Kutyifa V, Beck C, Brown MW, Cannom D, Daubert J, Estes M, Greenberg H, Goldenberg I, Hammes S, Huang D, Klein H, Knops R, Kosiborod M, Poole J, Schuger C, Singh JP, Solomon S, Wilber D, Zareba W, Moss AJ. Multicenter automatic defibrillator implantation trial–subcutaneous implantable cardioverter defibrillator (madit s-icd): Design and clinical protocol. Am Heart J. 2017;189:158-166.
Document Type
Conference Proceeding
Publication Date
2017
Publication Title
Am Heart J
Abstract
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverterdefibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post–myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
Volume
189
First Page
158
